The #SNMMI 2023 Mid-Winter & ACNM Annual Meeting kicked off this morning with a "New Image Interpretation Training" session, where participants learned how to accurately interpret new diagnostic agents and identify quality improvement opportunities when delivering patient care.
Happy to welcome Drs. Gyu Seong Heo, Nicole McKay (@nicolesmckay) and Ashwin Singh Parihar (@TheNUCguy) as our newest instructors. They're great additions to our Precision Radiotheranostics Translation & Neuroimaging Labs Research Centers. #MIRresearch https://t.co/z7WOIgQIfH
What a great start to the ACNM/@SNM_MI Hot Topics Webinar Series. Nothing gets hotter than #PSMA right now. It was a privilege to have Dr. Steven Rowe @HopkinsNucs speak on PSMA PET. Excited for the amazing line-up of talks ahead.
#nucmed#radtwitter#FOAMed
A novel nuclear imaging probe can measure gastric cancer patients' response to treatment within days, a potential breakthrough for treatment-resistant cases. Read about research by @ShadiEsfahani using a 2018 RSNA Research Resident Grant. https://t.co/jy6a1Iw8dP #RandEFoundation
**CALL TO ACTION** CMS is proceeding with changes to the MPFS that mean SIGNIFICANT CUTS for #NuclearMedicine (9% or more). SNMMI and 200+ other societies are urging Congress to help. Please SUPPORT that message--write your members of Congress TODAY at https://t.co/1ocY4dqxLH.
What's the buzz with Fibroblast activation protein? 68Ga-FAPI is the new radiotracer on the block that's challenging the likes of 18F-FDG. How does FAPI PET perform in breast cancer? - see for urself in this #RadInTraining#InAMinute
@RadITrainEditor @RSNA@radiology_rsna
A 2-year life-changing postdoctoral training experience with the incredible Dr. Julie Price (T32 Postdoc)! Training in multimodal neuroimaging (PET/MR) focusing on key research areas in Alzheimer’s disease and related dementias
Please share widely! #ENDALZ
https://t.co/MCJ75oJQse
#SNMMI21 Late-Breaking Session Panelists Added! “PSMA Radioligand Therapy: Updates from the VISION Trial.” The Phase 3 #VISIONTrial is evaluating the efficacy of 177Lu-PSMA-617 (LuPSMA) in the treatment of patients with PSMA-positive metastatic castrate-resistant prostate cancer.
Thomas J. Ruth, PhD, known for his contributions to nuclear medicine and nuclear chemistry, has been named as this year’s recipient of the SNMMI Georg Charles de Hevesy Nuclear Pioneer Award. Congratulations Dr. Ruth! #SNMMI21#NuclearMedicine
I'd like to congratulate @ShadiEsfahani, whose Research Seed Grant application was among @RSNA's top-ranked and approved for funding by the R&E Board of Trustees. Well done! #MGH#Radiology